

Roberto Iacovelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3233480/publications.pdf>

Version: 2024-02-01

216
papers

5,005
citations

87888

38
h-index

118850

62
g-index

222
all docs

222
docs citations

222
times ranked

7990
citing authors

#	ARTICLE	IF	CITATIONS
1	MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. <i>Journal of Clinical Pathology</i> , 2022, 75, 39-44.	2.0	7
2	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210795.	3.2	10
3	Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?. <i>Anticancer Research</i> , 2022, 42, 1487-1493.	1.1	7
4	Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations. <i>Cancer Treatment Reviews</i> , 2022, 105, 102379.	7.7	9
5	New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 106, 102377.	7.7	20
6	The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer. <i>Anticancer Research</i> , 2022, 42, 165-172.	1.1	4
7	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 727.	2.5	3
8	Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 498.e1-498.e9.	1.9	3
9	Methylation study of the Paris system for reporting urinary (TPS) categories. <i>Journal of Clinical Pathology</i> , 2021, 74, 102-105.	2.0	7
10	Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. <i>European Urology Oncology</i> , 2021, 4, 274-281.	5.4	7
11	Second-line treatment in renal cell carcinoma: clinical experience and decision making. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110228.	2.0	6
12	Prevalence of Prostate Cancer at Different Clinical Stages in Italy: Estimated Burden of Disease Based on a Modelling Study. <i>Biology</i> , 2021, 10, 210.	2.8	4
13	Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1029-1054.	2.4	11
14	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. <i>Targeted Oncology</i> , 2021, 16, 625-632.	3.6	6
15	2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1203-1206.	2.4	2
16	Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1-4.	2.4	1
17	Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer. <i>Annals of Oncology</i> , 2021, 32, 1192-1193.	1.2	0
18	Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. <i>European Urology</i> , 2021, 80, 497-506.	1.9	16

#	ARTICLE	IF	CITATIONS
19	Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis. <i>Cancer Treatment Reviews</i> , 2021, 100, 102295.	7.7	20
20	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110196.	3.2	36
21	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. <i>World Journal of Clinical Oncology</i> , 2021, 12, 1037-1046.	2.3	2
22	Treatment Outcome of metastatic lesions from renal cell carcinoma under Going Extra-cranial stereotactic body radiotherapy: The together retrospective study. <i>Cancer Treatment and Research Communications</i> , 2020, 22, 100161.	1.7	18
23	Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta-analysis of registrational phase III studies. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 199-206.	3.9	20
24	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	3.7	22
25	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , 2020, 15, 495-501.	3.6	28
26	The prognostic value of pain in castration-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 654-660.	3.9	7
27	Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 798.e17-798.e24.	1.6	6
28	Patients with sarcomatoid renal cell carcinoma “re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020, 136, 195-203.	2.8	47
29	Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. <i>Nature Communications</i> , 2020, 11, 4333.	12.8	82
30	Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. <i>Lancet Oncology</i> , The, 2020, 21, 1513-1525.	10.7	35
31	629P Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) vs abiraterone or enzalutamide in the CARD study. <i>Annals of Oncology</i> , 2020, 31, S519-S520.	1.2	1
32	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 477-488.	1.9	15
33	Biomarkers of response to advanced prostate cancer therapy. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 195-205.	3.1	12
34	The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients’s Age: A Systematic Review and Meta-Analysis. <i>Journal of Immunotherapy</i> , 2020, 43, 95-103.	2.4	7
35	Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5559-5559.	1.6	2
36	Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 16-16.	1.6	3

#	ARTICLE	IF	CITATIONS
37	CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.. Journal of Clinical Oncology, 2020, 38, 5569-5569.	1.6	1
38	Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).. Journal of Clinical Oncology, 2020, 38, TPS762-TPS762.	1.6	1
39	Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study.. Journal of Clinical Oncology, 2020, 38, TPS596-TPS596.	1.6	0
40	Enzalutamide (E) re-challenge as second-line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with first-line enzalutamide + docetaxel (D): Preliminary results of a post-progression analysis of CHEIRON trial.. Journal of Clinical Oncology, 2020, 38, 123-123.	1.6	0
41	PD16-08â€fEFFECT OF CABAZITAXEL VS ABIRATERONE OR ENZALUTAMIDE ON PATIENT-REPORTED OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A PRE-PLANNED EQ-5D-5L ANALYSIS OF THE CARD STUDY. Journal of Urology, 2020, 203, .	0.4	0
42	Toward a genome-based treatment landscape for renal cell carcinoma. Critical Reviews in Oncology/Hematology, 2019, 142, 141-152.	4.4	15
43	Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study). Annals of Oncology, 2019, 30, v333.	1.2	0
44	CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology, 2019, 30, v882-v883.	1.2	3
45	Positive Association between Preoperative Total Testosterone and Lymph Node Invasion in Intermediate Risk Prostate Cancer. Current Urology, 2019, 12, 216-222.	0.6	1
46	Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC). Annals of Oncology, 2019, 30, v372-v373.	1.2	2
47	Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. Cancers, 2019, 11, 1525.	3.7	28
48	Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. Journal of Translational Medicine, 2019, 17, 296.	4.4	13
49	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. New England Journal of Medicine, 2019, 381, 2506-2518.	27.0	403
50	Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis. Seminars in Oncology, 2019, 46, 65-72.	2.2	14
51	Cabozantinib-related pneumothorax in rapidly responding patients with renal cell carcinoma. Lancet Oncology, The, 2019, 20, e124.	10.7	1
52	Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions. Critical Reviews in Oncology/Hematology, 2019, 139, 83-86.	4.4	7
53	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 529.e1-529.e7.	1.6	5
54	Cabozantinibâ€related cardiotoxicity: a prospective analysis in a <i>realâ€world</i> cohort of metastatic renal cell carcinoma patients. British Journal of Clinical Pharmacology, 2019, 85, 1283-1289.	2.4	21

#	ARTICLE	IF	CITATIONS
55	PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019, 11, 921-930.	2.0	8
56	PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer. <i>Journal of Immunotherapy</i> , 2019, 42, 269-273.	2.4	10
57	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 917-927.	1.5	3
58	Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document. <i>Cancers</i> , 2019, 11, 1908.	3.7	1
59	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 42-45.	1.3	20
60	Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer. <i>Cancers</i> , 2019, 11, 30.	3.7	7
61	Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e150-e155.	1.9	9
62	Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e187-e194.	1.9	14
63	A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 148-148.	1.6	6
64	Fecal microbiota transplantation for TKI-induced diarrhea in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 615-615.	1.6	4
65	A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5050-5050.	1.6	0
66	Circulating tumor cells in genitourinary tumors. <i>Therapeutic Advances in Urology</i> , 2018, 10, 65-77.	2.0	14
67	The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e645-e653.	1.9	115
68	The development of PARP as a successful target for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 161-175.	2.4	16
69	Renal cell carcinoma in one year: Going inside the news of 2017 " A report of the main advances in RCC cancer research. <i>Cancer Treatment Reviews</i> , 2018, 67, 29-33.	7.7	8
70	The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. <i>Pathology and Oncology Research</i> , 2018, 24, 447-456.	1.9	20
71	Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study. <i>Annals of Oncology</i> , 2018, 29, viii316.	1.2	2
72	Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 526.e13-526.e18.	1.6	10

#	ARTICLE	IF	CITATIONS
73	ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance. <i>Pathology Research and Practice</i> , 2018, 214, 1675-1680.	2.3	1
74	Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer. <i>Targeted Oncology</i> , 2018, 13, 649-655.	3.6	18
75	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 355-359.e1.	1.9	31
76	Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience. <i>Anticancer Research</i> , 2018, 38, 4913-4918.	1.1	3
77	Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 937-945.	3.1	13
78	Positive Association between Preoperative Total Testosterone Levels and Risk of Positive Surgical Margins by Prostate Cancer: Results in 476 Consecutive Patients Treated Only by Radical Prostatectomy. <i>Urologia Internationalis</i> , 2018, 101, 38-46.	1.3	27
79	Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1069-e1071.	1.9	19
80	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e945-e951.	1.9	30
81	De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. <i>Cancer Treatment Reviews</i> , 2018, 70, 67-74.	7.7	41
82	Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 70, 112-117.	7.7	17
83	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. <i>Future Oncology</i> , 2018, 14, 2559-2564.	2.4	6
84	De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 482-484.	1.9	4
85	The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2018, 29, 705-709.	1.4	2
86	NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4602-TPS4602.	1.6	3
87	Relationship and Predictive Role of the Dual Expression of FGFR and IL-8 in Metastatic Renal Cell Carcinoma Treated with Targeted Agents. <i>Anticancer Research</i> , 2018, 38, 3105-3110.	1.1	4
88	Re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. <i>Eur Urol</i> 2017;71:970-8. <i>European Urology</i> , 2017, 71, e175-e176.	1.9	0
89	Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. <i>Cancer Treatment Reviews</i> , 2017, 54, 68-73.	7.7	64
90	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 541.e7-541.e13.	1.6	10

#	ARTICLE	IF	CITATIONS
91	Future perspectives for personalized immunotherapy in renal cell carcinoma. Expert Opinion on Biological Therapy, 2017, 17, 1049-1052.	3.1	13
92	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. Immunotherapy, 2017, 9, 579-587.	2.0	11
93	Adjuvant therapy in renal cell carcinoma. Cancer Treatment Reviews, 2017, 60, 152-157.	7.7	35
94	Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. European Journal of Cancer, 2017, 83, 237-246.	2.8	30
95	Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors. Anti-Cancer Drugs, 2017, 28, 206-212.	1.4	9
96	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. Clinical Colorectal Cancer, 2017, 16, e191-e198.	2.3	12
97	Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP). Annals of Oncology, 2017, 28, v319-v320.	1.2	1
98	CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure. Annals of Oncology, 2017, 28, vi17.	1.2	0
99	Wide spectrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. Oncotarget, 2017, 8, 7328-7335.	1.8	19
100	Cathepsin K Expression in Castration-Resistant Prostate Carcinoma: A Therapeutical Target for Patients at Risk for Bone Metastases. International Journal of Biological Markers, 2017, 32, 243-247.	1.8	10
101	Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors. Journal of Onco-Nephrology, 2017, 1, 132-142.	0.6	4
102	Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.. Journal of Clinical Oncology, 2017, 35, 5030-5030.	1.6	5
103	Changes in tumor burden and IMDC class after active surveillance (AS) for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2017, 35, 435-435.	1.6	2
104	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. Current Drug Metabolism, 2017, 18, 692-699.	1.2	7
105	Patients with metastatic castration-resistant prostate cancer (mCRPC) are primary resistant (PR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA.. Journal of Clinical Oncology, 2017, 35, e585-e585.	1.6	0
106	Patients with metastatic castration-resistant prostate cancer (mCRPC) who are long-term responders (LTR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA.. Journal of Clinical Oncology, 2017, 35, 254-254.	1.6	0
107	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in pts with metastatic castration-resistant prostate cancer (mCRPC) receiving a new agent (NA)- based third-line treatment: Final results from a multicenter Italian study.. Journal of Clinical Oncology, 2017, 35, 230-230.	1.6	0
108	Localized prostate cancer genotyping: another step towards personalized therapy. Translational Cancer Research, 2017, 6, S246-S248.	1.0	0

#	ARTICLE	IF	CITATIONS
109	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)- based third line treatment: Final results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16521-e16521.	1.6	0
110	The impact of kidney function on the efficacy and safety of pazopanib in metastatic renal cell carcinoma (mRCC) patients: CORE-URO-01 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16063-e16063.	1.6	0
111	Immune checkpoint inhibitors and prostate cancer: a new frontier?. <i>Oncology Reviews</i> , 2016, 10, 293.	1.8	47
112	Modified BEP chemotherapy in patients with testicular germ-cell tumors treated at a Comprehensive Cancer Center. <i>Annals of Oncology</i> , 2016, 27, iv29.	1.2	0
113	The prospect of precision therapy for renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2016, 49, 37-44.	7.7	46
114	Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer. <i>Targeted Oncology</i> , 2016, 11, 569-577.	3.6	15
115	Drug-drug interactions between abiraterone (ABI) or enzalutamide (ENZ) and concomitant medications in patients with metastatic castration resistant prostate cancer (mCRPC). <i>Annals of Oncology</i> , 2016, 27, iv34.	1.2	2
116	Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer. <i>Future Oncology</i> , 2016, 12, 2001-2008.	2.4	6
117	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. <i>Targeted Oncology</i> , 2016, 11, 143-148.	3.6	152
118	Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 324-331.	4.4	11
119	Metabolic phenotype of bladder cancer. <i>Cancer Treatment Reviews</i> , 2016, 45, 46-57.	7.7	201
120	Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. <i>Targeted Oncology</i> , 2016, 11, 337-343.	3.6	23
121	Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 24-28.	4.4	21
122	Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. <i>Clinical Interventions in Aging</i> , 2015, 10, 127.	2.9	2
123	Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2015, 9, 263.	0.6	6
124	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 156-166.	4.4	61
125	Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. <i>Therapeutic Advances in Urology</i> , 2015, 7, 59-68.	2.0	2
126	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. <i>European Journal of Cancer</i> , 2015, 51, 587-594.	2.8	425

#	ARTICLE	IF	CITATIONS
127	Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 1905-1910.	0.4	11
128	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, <i>RAS-BRAF</i> wild-type colorectal cancer receiving cetuximab or panitumumab. <i>International Journal of Cancer</i> , 2015, 137, 1467-1474.	5.1	33
129	Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. <i>European Journal of Cancer</i> , 2015, 51, 473-481.	2.8	17
130	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. <i>Annals of Surgical Oncology</i> , 2015, 22, 2094-2100.	1.5	72
131	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. <i>Annals of Oncology</i> , 2015, 26, 2107-2113.	1.2	85
132	Time from Nephrectomy as a Prognostic Factor in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapies: Overall Results from a Large Cohort of Patients. <i>Oncology</i> , 2015, 88, 133-138.	1.9	4
133	The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2015, 51, 1970-1977.	2.8	31
134	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 581-588.	2.4	52
135	Sunitinib 2 weeks on, 1 off: strengths and weaknesses. <i>Annals of Oncology</i> , 2015, 26, 1511-1512.	1.2	2
136	Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2015, 7, 286-294.	2.0	5
137	Everolimus and Temozolomide Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 137-141.	1.9	28
138	Emerging tyrosine kinase inhibitors for the treatment of renal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 379-392.	2.4	3
139	The origin of prostate metastases: emerging insights. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 765-773.	5.9	30
140	Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2015, 68, 154-160.	1.9	53
141	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 41-47.	0.4	58
142	Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2015, 136, 1-10.	5.1	47
143	The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?. <i>PLoS ONE</i> , 2015, 10, e0120427.	2.5	9
144	Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. <i>Oncotarget</i> , 2015, 6, 32161-32168.	1.8	28

#	ARTICLE	IF	CITATIONS
145	Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer: A Systematic Review and Meta-Analysis. <i>Current Drug Targets</i> , 2015, 16, 164-170.	2.1	47
146	Clinical outcome and prognostic factors in renal medullary carcinoma. A pooled analysis from 18 years of medical literature.. <i>Canadian Urological Association Journal</i> , 2015, 9, 172.	0.6	44
147	Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status. <i>PLoS ONE</i> , 2014, 9, e92147.	2.5	18
148	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.. <i>Canadian Urological Association Journal</i> , 2014, 8, 121.	0.6	8
149	Targeted treatments in advanced renal cell carcinoma: focus on axitinib. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 107.	0.7	5
150	Clinical and pathological features of primary renal angiosarcoma.. <i>Canadian Urological Association Journal</i> , 2014, 8, 223.	0.6	13
151	Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma. <i>British Journal of Cancer</i> , 2014, 110, 1778-1784.	6.4	50
152	First line treatment of metastatic renal cell carcinoma. <i>Cancer Biology and Therapy</i> , 2014, 15, 19-21.	3.4	7
153	Salvage therapy for recurrence of bladder cancer: do we need a uniform approach?. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 397-399.	3.1	0
154	FOLFOX-4 Chemotherapy for Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma. <i>Oncologist</i> , 2014, 19, 845-850.	3.7	48
155	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. <i>Future Oncology</i> , 2014, 10, 1741-1750.	2.4	12
156	FOLFIRI with cetuximab or bevacizumab: FIRE-3. <i>Lancet Oncology</i> , The, 2014, 15, e581.	10.7	1
157	Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1228-1237.	2.4	39
158	Management of Metastatic Renal Cell Carcinoma Progressed After Sunitinib or Another Antiangiogenic Treatment. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 611-615.	1.3	11
159	Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. <i>Future Oncology</i> , 2014, 10, 1361-1372.	2.4	9
160	Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies. <i>PLoS ONE</i> , 2014, 9, e108940.	2.5	55
161	Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 321-331.	5.9	27
162	Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data. <i>European Urology</i> , 2014, 65, 713-720.	1.9	71

#	ARTICLE	IF	CITATIONS
163	Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2014, 135, 763-773.	5.1	43
164	Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 271-275.	7.7	84
165	Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 929-938.	2.4	65
166	Study design and clinical evidence in mRCC. <i>Cancer Biology and Therapy</i> , 2014, 15, 486-488.	3.4	2
167	Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 471-471.	1.6	8
168	Role of MGMT as biomarker in colorectal cancer. <i>World Journal of Clinical Cases</i> , 2014, 2, 835.	0.8	27
169	Rationale and Protocol of SOAP: A Phase II Study to Evaluate the Efficacy of Sorafenib as Second-Line Treatment after Pazopanib in Patients with Advanced Renal Cell Carcinoma. <i>Tumori</i> , 2014, 100, e282-e285.	1.1	0
170	Prognostic value of flare-up phenomenon after discontinuation of sunitinib (SU) or pazopanib (PA) in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 448-448.	1.6	0
171	Treatment of collecting duct carcinoma: current status and future perspectives. <i>Anticancer Research</i> , 2014, 34, 1027-30.	1.1	20
172	Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma. <i>Tumori</i> , 2014, 100, e282-5.	1.1	0
173	Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2013, 113, 397-401.	2.9	17
174	Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2013, 109, 1755-1759.	6.4	79
175	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. <i>European Journal of Cancer</i> , 2013, 49, 2134-2142.	2.8	60
176	Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 323-327.	3.9	10
177	Clinical and Pathological Features of Primary Neuroectodermal Tumor/Ewing Sarcoma of the Kidney. <i>Urology</i> , 2013, 82, 382-386.	1.0	65
178	Multimodality Treatment of Gynecomastia in Patients Receiving Antiandrogen Therapy for Prostate Cancer in the Era of Abiraterone Acetate and New Antiandrogen Molecules. <i>Oncology</i> , 2013, 84, 92-99.	1.9	9
179	Reply to "mTOR inhibitor-related pulmonary toxicity; incidence even higher". <i>Acta Oncologica</i> , 2013, 52, 1235-1235.	1.8	0
180	Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. <i>Cancer</i> , 2013, 119, 3377-3384.	4.1	170

#	ARTICLE	IF	CITATIONS
181	Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 431-431.	1.6	1
182	Clinical outcome (CO) and predictive factors (PRE) evaluation of young (â‰¥ 60 years) castration-resistant prostate cancer (CRPC) patients, treated with docetaxel (DOC): Preliminary results of an Italian multicenter retrospective study (CYCLOP study).. <i>Journal of Clinical Oncology</i> , 2013, 31, e16031-e16031.	1.6	0
183	Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma. <i>Anticancer Research</i> , 2013, 33, 5663-6.	1.1	7
184	Gemcitabine-Induced Extensive Skin Necrosis. <i>Case Reports in Medicine</i> , 2012, 2012, 1-3.	0.7	8
185	Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. <i>Cancer Biology and Therapy</i> , 2012, 13, 1001-1008.	3.4	6
186	Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. <i>British Journal of Cancer</i> , 2012, 107, 1227-1232.	6.4	18
187	Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. <i>Acta OncolÃ³gica</i> , 2012, 51, 873-879.	1.8	66
188	Post-docetaxel therapy in castration resistant prostate cancer â€” the forest is growing in the desert. <i>Therapeutic Advances in Urology</i> , 2012, 4, 107-111.	2.0	2
189	Abiraterone acetate in castration-resistant prostate cancer. <i>Anti-Cancer Drugs</i> , 2012, 23, 247-254.	1.4	7
190	Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. <i>BJU International</i> , 2012, 110, 1747-1753.	2.5	60
191	Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. <i>Clinical and Experimental Nephrology</i> , 2012, 16, 464-467.	1.6	33
192	Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib. <i>International Journal of Dermatology</i> , 2012, 51, 221-222.	1.0	11
193	Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. <i>BJU International</i> , 2012, 110, 692-698.	2.5	39
194	Clinical and pathological features of primary renal synovial sarcoma: analysis of 64 cases from 11 years of medical literature. <i>BJU International</i> , 2012, 110, 1449-1454.	2.5	48
195	Tumor burden as an independent prognostic factor in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 397-397.	1.6	11
196	Prognostic role of body composition parameters in renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4621-4621.	1.6	0
197	Overall survival (OS) in metastatic renal cell carcinoma (mRCC) sequentially treated with different targeted therapies (TTs): Results from a large cohort of patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4629-4629.	1.6	0
198	Umbilical Node as First Clinical Appearance in a Patient with a High Tumor Burden. <i>American Surgeon</i> , 2011, 77, 248-249.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1631-1640.	2.4	17
200	Umbilical node as first clinical appearance in a patient with a high tumor burden. <i>American Surgeon</i> , 2011, 77, E248-9.	0.8	0
201	Circulating tumor cells and "suspicious objects" evaluated through CellSearch [®] in metastatic renal cell carcinoma. <i>Anticancer Research</i> , 2011, 31, 4219-21.	1.1	49
202	The End of Chemotherapy in Renal Cell Carcinoma: For Much But Not for All. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 522-523.	1.3	0
203	Molecular markers in circulating tumour cells from metastatic colorectal cancer patients. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 2073-2077.	3.6	69
204	Renal Cell Carcinoma: Incidence and Cost Estimation in the Era of Targeted Therapy. <i>Tumori</i> , 2010, 96, 361-361.	1.1	1
205	Is It Possible to Optimize the use of Targeted Therapies in the Treatment of Renal Cell Carcinoma?. <i>Tumori</i> , 2010, 96, 794-795.	1.1	2
206	Neoadjuvant targeted therapy in renal cell carcinoma. <i>Nature Reviews Urology</i> , 2010, 7, 1-1.	3.8	1
207	Past, Present and Future of Targeted Therapy in Solid Tumors. <i>Current Cancer Drug Targets</i> , 2010, 10, 433-461.	1.6	30
208	Renal cell carcinoma: incidence and cost estimation in the era of targeted therapy. <i>Tumori</i> , 2010, 96, 361.	1.1	1
209	Dermatomyositis as first clinical appearance for a thymic epidermoid cell carcinoma. <i>Acta Biomedica</i> , 2010, 81, 68-71.	0.3	3
210	Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma?. <i>Tumori</i> , 2010, 96, 794-5.	1.1	1
211	Hepatocellular carcinoma in Central, Eastern, and Southern Europe. What Future after the SHARP Trial?. <i>Open Medicine (Poland)</i> , 2009, 4, 138-139.	1.3	0
212	Neo-adjuvant and adjuvant chemotherapy in bladder cancer. <i>Annals of Oncology</i> , 2007, 18, vi162-vi163.	1.2	2
213	Clinical management and follow-up of squamous intraepithelial cervical lesions during pregnancy and postpartum. <i>Anticancer Research</i> , 2007, 27, 2743-6.	1.1	21
214	Verrucous carcinoma of the cervix: detection of carcinogenetic human papillomavirus types and their role during follow-up. <i>Anticancer Research</i> , 2007, 27, 4491-4.	1.1	10
215	Follow-up of high-grade squamous intra-epithelial lesions (H-SILs) in human immunodeficiency virus (HIV)-positive and human papillomavirus (HPV)-positive women. analysis of risk factors. <i>Anticancer Research</i> , 2006, 26, 3167-70.	1.1	6
216	Prevalence of acetowhite areas in male partners of women affected by HPV and squamous intra-epithelial lesions (SIL) and their prognostic significance. A multicenter study. <i>Anticancer Research</i> , 2006, 26, 3171-4.	1.1	7